All In Biotech

Drug Trial Radar · NCT01922102

Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

A 12-month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Individualized Regimens of 0.5mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Last checked: Nov 20, 2026Latest source record: Jun 24, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 457 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

457

Actual

Start

Sep 11, 2013

Primary completion

Sep 14, 2016

Study completion Sep 14, 2016

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 14, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia (PM)

Conditions

  • Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)

Interventions

  • Ranibizumab 0.5mgDrug

    0.5 mg ranibizumab (intravitreal injections)

  • Ranibizumab 0.5 mgDrug

    0.5 mg ranibizumab (intravitreal injections)

  • Verteporfin PDTDrug

    Verteporfin for intravenous injection delivered by intravenous infusion followed by the light application

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 3Time frame: From Baseline to Month 3

Locations

47 sites in 6 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Chongqing, China

  • Novartis Investigative Site

    Shanghai, China

  • Novartis Investigative Site

    Shanghai, China

  • Novartis Investigative Site

    Shanghai, China

  • Novartis Investigative Site

    Beijing, Beijing Municipality, China

  • Novartis Investigative Site

    Beijing, Beijing Municipality, China

  • Novartis Investigative Site

    Chongqing, Chongqing Municipality, China

  • Novartis Investigative Site

    Shantou, Guangdong, China

  • Novartis Investigative Site

    Harbin, Heilongjiang, China

  • Novartis Investigative Site

    Wuhan, Hubei, China

  • Novartis Investigative Site

    Wuhan, Hubei, China

  • Novartis Investigative Site

    Changsha, Hunan, China

  • Novartis Investigative Site

    Changsha, Hunan, China

  • Novartis Investigative Site

    Nanjing, Jiangsu, China

  • Novartis Investigative Site

    Nanjing, Jiangsu, China

  • Novartis Investigative Site

    Wuxi, Jiangsu, China

  • Novartis Investigative Site

    Nanchang, Jiangxi, China

  • Novartis Investigative Site

    Qingdao, Shandong, China

  • Novartis Investigative Site

    Xi’an, Shanxi, China

  • Novartis Investigative Site

    Chengdu, Sichuan, China

  • Novartis Investigative Site

    Tianjin, Tianjin Municipality, China

  • Novartis Investigative Site

    Tianjin, Tianjin Municipality, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, China

  • Novartis Investigative Site

    Wenzhou, Zhejiang, China

  • Novartis Investigative Site

    Hong Kong, Hong Kong

  • Novartis Investigative Site

    Angamaly, India

  • Novartis Investigative Site

    New Delhi, India

  • Novartis Investigative Site

    Chandīgarh, Haryana, India

  • Novartis Investigative Site

    Bangalore, Karnataka, India

  • Novartis Investigative Site

    Vanchiyoor, Kerala, India

  • Novartis Investigative Site

    Bhubaneswar, Odisha, India

  • Novartis Investigative Site

    Chennai, Tamil Nadu, India

  • Novartis Investigative Site

    Chennai, Tamil Nadu, India

  • Novartis Investigative Site

    Coimbatore, Tamil Nadu, India

  • Novartis Investigative Site

    Hyderabad, Telangana, India

  • Novartis Investigative Site

    Manila, National Capital Region, Philippines

  • Novartis Investigative Site

    Manila, National Capital Region, Philippines

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.